Baird initiated coverage of Crispr Therapeutics with a Neutral rating and $46 price target. The company is is focused on the applying Crisper gene editing to create novel therapeutics and its CTX001 represents a potentially curative one-time cell therapy for sickle cell disease and transfusion dependent beta-thalassemia, the analyst tells investors in a research note. The firm anticipates CTX001 will see "substantial uptake" after securing a potential U.S. approval in late-2023, but believes consensus expectations largely reflect a strong launch. It is also "generally cautious" on the company’s CAR-T portfolio. Baird views the shares as fairly valued.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CRSP:
- Crispr Therapeutics price target lowered to $102 from $110 at Oppenheimer
- Crispr Therapeutics reports Q4 EPS ($1.41) vs. ($1.84) y/y
- Crispr Therapeutics price target lowered to $82 from $122 at Needham
- Crispr Therapeutics price target lowered to $123 from $153 at Chardan
- Crispr Therapeutics price target lowered to $65 from $78 at Credit Suisse
